Literature DB >> 285681

Labetalol: bioavailability, drug plasma levels, plasma renin and catecholamines in acute and chronic treatment of resistant hypertension.

W J Louis, N Christophidis, M Brignell, V Vijayasekaran, J McNeil, F J Vajda.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 285681     DOI： 10.1111/j.1445-5994.1978.tb04847.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN： 0004-8291


× No keyword cloud information.
  10 in total

1.  The effects of a single dose of dilevalol on [3H]-noradrenaline plasma kinetics and plasma lipoprotein cholesterol concentrations.

Authors:  L G Howes; P R Rowe; H Krum; W J Louis
Journal:  Br J Clin Pharmacol       Date:  1990-03       Impact factor: 4.335

2.  Pharmacokinetics and systemic availability of the antihypertensive agent indoramin and its metabolite 6-hydroxyindoramin in healthy subjects.

Authors:  D M Pierce; S M Abrams; R A Franklin
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

3.  Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects.

Authors:  J J McNeil; A E Anderson; W J Louis; D J Morgan
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

4.  Labetolol in patients with hypertension and varying degrees of renal impairment.

Authors:  E G Breen; M Lombard; A Watson; J A Keogh
Journal:  Ir J Med Sci       Date:  1984-10       Impact factor: 1.568

5.  Effects of chronic alpha and beta adrenoceptor blockade with labetalol on plasma catecholamines and renal function in hypertension.

Authors:  G Keusch; P Weidmann; W H Ziegler; R de Châtel; F C Reubi
Journal:  Klin Wochenschr       Date:  1980-01-02

Review 6.  Clinical pharmacokinetics of labetalol.

Authors:  J J McNeil; W J Louis
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

Review 7.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

8.  Elimination kinetics of labetalol in severe renal failure.

Authors:  A J Wood; D G Ferry; R R Bailey
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

9.  Labetalol steady-state pharmacokinetics in hypertensive patients.

Authors:  J J McNeil; A E Anderson; W J Louis; K Raymond
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 10.  Pharmacology of combined alpha-beta-blockade. I.

Authors:  W J Louis; J J McNeil; O H Drummer
Journal:  Drugs       Date:  1984       Impact factor: 9.546
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.